Metropolitan Life Insurance CO Adverum Biotechnologies, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $80 - $253	-24 Closed	0 $0
Q1 2021 Jun 26, 2023	BUY	$9.26 - $14.36 $222,684 - $345,329	24,048 New	24,048 $237 Million
Q1 2021 Mar 30, 2023	SELL	$9.26 - $14.36 $16,445 - $25,503	-1,776 Reduced 6.88%	24,048 $237,000
Q1 2021 May 14, 2021	SELL	$9.26 - $14.36 $238,908 - $370,488	-25,800 Reduced 99.91%	24 $237,000
Q4 2020 Jun 22, 2023	BUY	$9.84 - $14.26 $254,108 - $368,250	25,824 New	25,824 $279,000
Q3 2020 Jun 26, 2023	BUY	$10.3 - $21.64 $265,987 - $558,831	25,824 New	25,824 $265,000
Q3 2020 Mar 30, 2023	BUY	$10.3 - $21.64 $34,082 - $71,606	3,309 Added 14.7%	25,824 $265,000
Q3 2020 Nov 13, 2020	BUY	$10.3 - $21.64 $34,082 - $71,606	3,309 Added 14.7%	25,824 $266,000
Q2 2020 Jun 26, 2023	BUY	$8.53 - $25.64 $192,052 - $577,284	22,515 New	22,515 $470,000
Q2 2020 Mar 30, 2023	BUY	$8.53 - $25.64 $22,391 - $67,305	2,625 Added 13.2%	22,515 $470,000
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $22,391 - $67,305	2,625 Added 13.2%	22,515 $470,000
Q1 2020 Jul 12, 2023	BUY	$7.98 - $16.32 $158,722 - $324,604	19,890 New	19,890 $194,000
Q1 2020 Mar 30, 2023	BUY	$7.98 - $16.32 $41,136 - $84,129	5,155 Added 34.98%	19,890 $194,000
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $41,136 - $84,129	5,155 Added 34.98%	19,890 $194,000
Q4 2019 Jul 12, 2023	BUY	$5.12 - $12.22 $75,443 - $180,061	14,735 New	14,735 $169,000
Q4 2019 Mar 30, 2023	SELL	$5.12 - $12.22 $30,295 - $72,305	-5,917 Reduced 28.65%	14,735 $169,000
Q4 2019 Feb 14, 2020	SELL	$5.12 - $12.22 $30,295 - $72,305	-5,917 Reduced 28.65%	14,735 $170,000
Q3 2019 Jul 12, 2023	BUY	$5.24 - $15.89 $108,216 - $328,160	20,652 New	20,652 $112,000
Q2 2019 Jul 12, 2023	BUY	$5.1 - $11.89 $105,325 - $245,552	20,652 New	20,652 $245,000
Q1 2019 Jul 13, 2023	BUY	$3.03 - $6.02 $62,575 - $124,325	20,652 New	20,652 $108,000
Q1 2019 Mar 30, 2023	BUY	$3.03 - $6.02 $62,575 - $124,325	20,652 New	20,652 $108,000
Q1 2019 May 16, 2019	SELL	$3.03 - $6.02 $218,317 - $433,753	-72,052 Reduced 77.72%	20,652 $108,000
Q1 2019 May 15, 2019	BUY	$3.03 - $6.02 $280,893 - $558,078	92,704 New	92,704 $11 Million
Q4 2018 Feb 14, 2019	SELL	$2.87 - $5.92 $12,579 - $25,947	-4,383 Closed	0 $0
Q3 2018 Jul 13, 2023	BUY	$4.5 - $7.6 $90,067 - $152,114	20,015 New	20,015 $121 Million
Q3 2018 Nov 14, 2018	SELL	$4.5 - $7.6 $70,344 - $118,803	-15,632 Reduced 78.1%	4,383 $27,000
Q2 2018 Aug 15, 2018	BUY	$5.3 - $6.9 $106,079 - $138,103	20,015 New	20,015 $0

Others Institutions Holding ADVM

# of Institutions

Shares Held

524K

Call Options Held

Put Options Held

Versant Venture Management, LLC San Francisco, CA

507K
Shares

$2.4 Million
9.32% of portfolio
Pinz Capital Management, LP New York, NY

15.7K
Shares

$74,418
0.03% of portfolio
American Portfolios Advisors Holbrook, NY

1.15K
Shares

$5,451
0.0% of portfolio

View Full List

About Adverum Biotechnologies, Inc.

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

More about ADVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account